

Title: α -amylase variants

inventor
FIELD OF THE INVENTION

The present invention relates to novel variants of parent
s Termamyl-like α -amylases with altered properties relative of the
parent alpha-amylase. Said properties include increased
stability, e.g., at acidic pH, e.g., at low calcium
concentrations and/or high temperatures. Such variants are
suitable for a number of applications, in particular, industrial
10 starch processing (e.g., starch liquefaction or
saccharification).

BACKGROUND OF THE INVENTION

α -Amylases (α -1,4-glucan-4-glucanohydrolases, EC 3.2.1.1)
15 constitute a group of enzymes which catalyze hydrolysis of
starch and other linear and branched 1,4-glucosidic oligo- and
polysaccharides.

There is a very extensive body of patent and scientific
literature relating to this industrially very important class of
20 enzymes. A number of α -amylase such as Termamyl-like α -
amylases variants are known from, e.g., WO 90/11352, WO
95/10603, WO 95/26397, WO 96/23873 and WO 96/23874.

WO 96/23874 provides the three-dimensional, X-ray crystal
structural data for a Termamyl-like α -amylase which consists of
25 the 300 N-terminal amino acid residues of the *B.*
amyloliquefaciens α -amylase and amino acids 301-483 of the C-
terminal end of the *B. licheniformis* α -amylase comprising the
amino acid sequence (the latter being available commercially
under the tradename TermamylTM), and which is thus closely
30 related to the industrially important *Bacillus* α -amylases (which
in the present context are embraced within the meaning of the
term "Termamyl-like α -amylases", and which include, *inter alia*,
the *B. licheniformis*, *B. amyloliquefaciens* and *B.*
stearothermophilus α -amylases). WO 96/23874 further describes
35 methodology for designing, on the basis of an analysis of the

structure of a parent Termamyl-like α -amylase, variants of the parent Termamyl-like α -amylase which exhibit altered properties relative to the parent.

5 BRIEF DISCLOSURE OF THE INVENTION

The present invention relates to novel α -amylolytic variants (mutants) of a Termamyl-like α -amylase, in particular variants exhibiting increased stability at acidic pH at high temperatures (relative to the parent) which are advantageous in
10 connection with, e.g., the industrial processing of starch (starch liquefaction, saccharification and the like) as described in US Patent No. 3,912,590 and EP patent publications Nos. 252,730 and 63,909.

15 Starch conversion

A "traditional" starch conversion process degrading starch to lower molecular weight carbohydrate components such as sugars or fat replacers includes a debranching step.

20 "Starch to sugar" conversion

In the case of converting starch into a sugar the starch is depolymerized. A such depolymerization process consists of a pretreatment step and two or three consecutive process steps, viz. a liquefaction process, a saccharification process and
25 dependent on the desired end product optionally an isomerization process.

Pre-treatment of native starch

Native starch consists of microscopic granules which are
30 insoluble in water at room temperature. When an aqueous starch slurry is heated, the granules swell and eventually burst, dispersing the starch molecules into the solution. During this "gelatinization" process there is a dramatic increase in viscosity. As the solids level is 30-40% in a typically
35 industrial process, the starch has to be thinned or "liquefied" so that it can be handled. This reduction in viscosity is today

mostly obtained by enzymatic degradation.

Liquefaction

During the liquefaction step, the long chained starch is degraded into branched and linear shorter units (maltodextrins) by an α -amylase (e.g., Termamyl™ SEQ ID NO: 4 herein). The liquefaction process is carried out at 105-110°C for 5 to 10 minutes followed by 1-2 hours at 95°C. The pH lies between 5.5 and 6.2. In order to ensure an optimal enzyme stability under these conditions, 1 mM of calcium is added (40 ppm free calcium ions). After this treatment the liquefied starch will have a "dextrose equivalent" (DE) of 10-15.

Saccharification

After the liquefaction process the maltodextrins are converted into dextrose by addition of a glucoamylase (e.g., AMG™) and a debranching enzyme, such as an isoamylase (US Patent 4,335,208) or a pullulanase (e.g., Promozyme™) (US Patent 4,560,651). Before this step the pH is reduced to a value below 4.5, maintaining the high temperature (above 95°C) to inactivate the liquefying α -amylase to reduce the formation of short oligosaccharide called "panose precursors" which cannot be hydrolyzed properly by the debranching enzyme.

The temperature is lowered to 60°C, and glucoamylase and debranching enzyme are added. The saccharification process proceeds for 24-72 hours.

Normally, when denaturing the α -amylase after the liquefaction step about 0.2-0.5% of the saccharification product is the branched trisaccharide 6²- α -glucosyl maltose (panose) which cannot be degraded by a pullulanase. If active amylase from the liquefaction step is present during saccharification (i.e., no denaturing), this level can be as high as 1-2%, which is highly undesirable as it lowers the saccharification yield significantly.

Isomerization

When the desired final sugar product is e.g. high fructose syrup the dextrose syrup may be converted into fructose.

- 5 After the saccharification process the pH is increased to a value in the range of 6-8, preferably pH 7.5, and the calcium is removed by ion exchange. The dextrose syrup is then converted into high fructose syrup using, e.g., an immobilized glucose isomerase (such as Sweetzyme™).

10

In the context of the invention the term "acidic pH" means a pH below 7.0, especially below the pH range in which industrial starch liquefaction processes are traditionally performed, as described above, which is between pH 5.5 and 6.2.

15

In the context of the present invention the term "low Calcium concentration" means concentrations below the normal level used in traditional industrial starch liquefaction processes, such as between 0-40 ppm, preferably between 10-30 ppm, such as between 15-25 ppm Calcium. Normal concentrations vary depending of the concentration of free Ca^{2+} in the corn. Normally a dosage corresponding to 1mM (40ppm) is added which together with the level in corn gives between 40 and 60 ppm free Ca^{2+} .

20

In the context of the invention the term "high temperature" means temperatures between 95 and 160°C, especially the temperature range in which industrial starch liquefaction processes are normally performed, which is between 95 and 105°C.

25

The invention further relates to DNA constructs encoding variants of the invention, to methods for preparing variants of the invention, and to the use of variants of the invention, alone or in combination with other α -amylolytic enzymes, in various industrial processes, in particular starch liquefaction.

30

35 Nomenclature

In the present description and claims, the conventional one-letter and three-letter codes for amino acid residues are used.

For ease of reference, α -amylase variants of the invention are described by use of the following nomenclature:

Original amino acid(s):position(s):substituted amino acid(s)

According to this nomenclature, for instance the substitution of alanine for asparagine in position 30 is shown as:

Ala30Asn or A30N

a deletion of alanine in the same position is shown as:

Ala30* or A30*

and insertion of an additional amino acid residue, such as lysine, is shown as:

Ala30AlaLys or A30AK

A deletion of a consecutive stretch of amino acid residues, such as amino acid residues 30-33, is indicated as (30-33)* or Δ (A30-N33).

Where a specific α -amylase contains a "deletion" in comparison with other α -amylases and an insertion is made in such a position this is indicated as:

*36Asp or *36D

for insertion of an aspartic acid in position 36

Multiple mutations are separated by plus signs, i.e.:

Ala30Asp + Glu34Ser or A30N+E34S

representing mutations in positions 30 and 34 substituting alanine and glutamic acid for asparagine and serine, respectively. Multiple mutation may also be separated as follows, i.e., meaning the same as the plus sign:

Ala30Asp/Glu34Ser or A30N/E34S

When one or more alternative amino acid residues may be inserted in a given position it is indicated as

A30N,E or

A30N or A30E

Furthermore, when a position suitable for modification is identified herein without any specific modification being suggested, it is to be understood that any amino acid residue may be substituted for the amino acid residue present in the position. Thus, for instance, when a modification of an alanine

in position 30 is mentioned, but not specified, it is to be understood that the alanine may be deleted or substituted for any other amino acid, i.e., any one of:
R,N,D,A,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V.

5

BRIEF DESCRIPTION OF THE DRAWING

Figure 1 is an alignment of the amino acid sequences of six parent Termamyl-like α -amylases in the context of the invention. The numbers on the Extreme left designate the respective amino acid sequences as follows:

1: SEQ ID NO: 2,

2: amylase

3: SEQ ID NO: 1,

4: SEQ ID NO: 5,

15 5: SEQ ID NO: 4,

6: SEQ ID NO: 3.

Figure 2 shows the PCR strategy used in Example 1.

20 DETAILED DISCLOSURE OF THE INVENTION

The Termamyl-like α -amylase

It is well known that a number of α -amylases produced by *Bacillus* spp. are highly homologous on the amino acid level. For instance, the *B. licheniformis* α -amylase comprising the amino acid sequence shown in SEQ ID NO: 4 (commercially available as Termamyl™) has been found to be about 89% homologous with the *B. amyloliquefaciens* α -amylase comprising the amino acid sequence shown in SEQ ID NO: 5 and about 79% homologous with the *B. stearothermophilus* α -amylase comprising the amino acid sequence shown in SEQ ID NO: 3. Further homologous α -amylases include an α -amylase derived from a strain of the *Bacillus* sp. NCIB 12289, NCIB 12512, NCIB 12513 or DSM 9375, all of which are described in detail in WO 95/26397, and the α -amylase described by Tsukamoto et al., Biochemical and Biophysical Research Communications, 151 (1988), pp. 25-31.

Still further homologous α -amylases include the α -amylase produced by the *B. licheniformis* strain described in EP 0252666 (ATCC 27811), and the α -amylases identified in WO 91/00353 and WO 94/18314. Other commercial Termamyl-like *B. licheniformis* α -amylases are Optitherm™ and Takatherm™ (available from Solvay), Maxamyl™ (available from Gist-brocades/Genencor), Spezym AA™ and Spezyme Delta AA™ (available from Genencor), and Keistase™ (available from Daiwa).

Because of the substantial homology found between these α -amylases, they are considered to belong to the same class of α -amylases, namely the class of "Termamyl-like α -amylases".

Accordingly, in the present context, the term "Termamyl-like α -amylase" is intended to indicate an α -amylase which, at the amino acid level, exhibits a substantial homology to Termamyl™, i.e., the *B. licheniformis* α -amylase having the amino acid sequence shown in SEQ ID NO: 4 herein. In other words, a Termamyl-like α -amylase is an α -amylase which has the amino acid sequence shown in SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7 or 8 herein, and the amino acid sequence shown in SEQ ID NO: 1 of WO 95/26397 (the same as the amino acid sequence shown as SEQ ID NO: 7 herein) or in SEQ ID NO: 2 of WO 95/26397 (the same as the amino acid sequence shown as SEQ ID NO: 8 herein) or in Tsukamoto et al., 1988, (which amino acid sequence is shown in SEQ ID NO: 6 herein) or i) which displays at least 60% homology (identity), preferred at least 70%, more preferred at least 75%, even more preferred at least 80%, especially at least 85%, especially preferred at least 90%, especially at least 95%, even especially more preferred at least 97%, especially at least 99% homology with at least one of said amino acid sequences shown in SEQ ID NOS 1: or 2 or 3 or 4 or 5 or 6 or 7 or 8 and/or ii) displays immunological cross-reactivity with an antibody raised against one or more of said α -amylases, and/or iii) is encoded by a DNA sequence which hybridizes, under the low to very high stringency conditions (said conditions described below) to the

DNA sequences encoding the above-specified α -amylases which are apparent from SEQ ID NOS: 9, 10, 11, 12, and 32, respectively, of the present application (which encodes the amino acid sequences shown in SEQ ID NOS: 1, 2, 3, 4, and 5 herein, 5 respectively), from SEQ ID NO: 4 of WO 95/26397 (which DNA sequence, together with the stop codon TAA, is shown in SEQ ID NO: 13 herein and encodes the amino acid sequence shown in SEQ ID NO: 8 herein) and from SEQ ID NO: 5 of WO 95/26397 (shown in SEQ ID NO: 14 herein), respectively.

10 In connection with property i), the "homology" (identity) may be determined by use of any conventional algorithm, preferably by use of the gap programme from the GCG package version 8 (August 1994) using default values for gap penalties, i.e., a gap creation penalty of 3.0 and gap extension penalty of 15 0.1 (Genetic Computer Group (1991) Programme Manual for the GCG Package, version 8, 575 Science Drive, Madison, Wisconsin, USA 53711).

The parent Termamyl-like α -amylase backbone may in an embodiment have an amino acid sequence which has a degree of 20 identity to SEQ ID NO: 4 of at least 65%, preferably at least 70%, preferably at least 75%, more preferably at least 80%, more preferably at least 85%, even more preferably at least about 90%, even more preferably at least 95%, even more preferably at least 97%, and even more preferably at least 99% identity 25 determined as described above

A structural alignment between Termamyl® (SEQ ID NO: 4) and a Termamyl-like α -amylase may be used to identify equivalent/corresponding positions in other Termamyl-like α -amylases. One method of obtaining said structural alignment is 30 to use the Pile Up programme from the GCG package using default values of gap penalties, i.e., a gap creation penalty of 3.0 and gap extension penalty of 0.1. Other structural alignment methods include the hydrophobic cluster analysis (Gaboriaud et al., (1987), FEBS LETTERS 224, pp. 149-155) and reverse threading 35 (Huber, T ; Torda, AE, PROTEIN SCIENCE Vol. 7, No. 1 pp. 142-149 (1998)).

For example, the corresponding positions, of target residues found in the C-domain of the *B. licheniformis* α -amylase, in the amino acid sequences of a number of Termamyl-like α -amylases which have already been mentioned are as follows:

5

Termamyl-like α -amylase

10	<i>B. lich.</i> (SEQ ID NO: 4)	S356	Y358	E376	S417	A420
	<i>B. amylo.</i> (SEQ ID NO: 5)	S356	Y358	E376	S417	A420
	<i>B. stearo.</i> (SEQ ID NO: 3)	----	Y361	----	----	----
	<i>Bac.WO 95/26397</i> (SEQ ID NO: 2)	----	Y363	----	S419	----
	<i>Bac.WO 95/26397</i> (SEQ ID NO: 1)	----	Y363	----	----	----

15

As will be described further below mutations of these conserved amino acid residues are very important in relation to increasing the stability at acidic pH and/or at low calcium concentration at high temperatures.

20

Property ii) (see above) of the α -amylase, i.e., the immunological cross reactivity, may be assayed using an antibody raised against, or reactive with, at least one epitope of the relevant Termamyl-like α -amylase. The antibody, which may either be monoclonal or polyclonal, may be produced by methods known in the art, e.g., as described by Hudson et al., Practical Immunology, Third edition (1989), Blackwell Scientific Publications. The immunological cross-reactivity may be determined using assays known in the art, examples of which are Western Blotting or radial immunodiffusion assay, e.g., as described by Hudson et al., 1989. In this respect, immunological cross-reactivity between the α -amylases having the amino acid sequences SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, or 8 respectively, have been found.

30

The oligonucleotide probe used in the characterization of the Termamyl-like α -amylase in accordance with property iii)

35

above may suitably be prepared on the basis of the full or partial nucleotide or amino acid sequence of the α -amylase in question.

Suitable conditions for testing hybridization involve
5 presoaking in 5xSSC and prehybridizing for 1 hour at -40°C in a solution of 20% formamide, 5xDenhardt's solution, 50mM sodium phosphate, pH 6.8, and 50mg of denatured sonicated calf thymus DNA, followed by hybridization in the same solution supplemented with 100mM ATP for 18 hours at -40°C , followed by three times
10 washing of the filter in 2xSSC, 0.2% SDS at 40°C for 30 minutes (low stringency), preferred at 50°C (medium stringency), more preferably at 65°C (high stringency), even more preferably at -75°C (very high stringency). More details about the hybridization method can be found in Sambrook et al., Molecular
15 Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor, 1989.

In the present context, "derived from" is intended not only to indicate an α -amylase produced or producible by a strain of the organism in question, but also an α -amylase encoded by a DNA sequence isolated from such strain and produced in a host or-
20 ganism transformed with said DNA sequence. Finally, the term is intended to indicate an α -amylase which is encoded by a DNA sequence of synthetic and/or cDNA origin and which has the identifying characteristics of the α -amylase in question. The term is also intended to indicate that the parent α -amylase may
25 be a variant of a naturally occurring α -amylase, i.e., a variant which is the result of a modification (insertion, substitution, deletion) of one or more amino acid residues of the naturally occurring α -amylase.

30 Parent hybrid α -amylases

The parent α -amylase (backbone) may be a hybrid α -amylase, i.e., an α -amylase which comprises a combination of partial amino acid sequences derived from at least two α -amylases.

The parent hybrid α -amylase may be one which on the basis of

amino acid homology and/or immunological cross-reactivity and/or DNA hybridization (as defined above) can be determined to belong to the Termamyl-like α -amylase family. In this case, the hybrid α -amylase is typically composed of at least one part of a
5 Termamyl-like α -amylase and part(s) of one or more other α -amylases selected from Termamyl-like α -amylases or non-Termamyl-like α -amylases of microbial (bacterial or fungal) and/or mammalian origin.

Thus, the parent hybrid α -amylase may comprise a combination
10 of partial amino acid sequences deriving from at least two Termamyl-like α -amylases, or from at least one Termamyl-like and at least one non-Termamyl-like bacterial α -amylase, or from at least one Termamyl-like and at least one fungal α -amylase. The Termamyl-like α -amylase from which a partial amino acid sequence
15 derives may, e.g., be any of those specific Termamyl-like α -amylase referred to herein.

For instance, the parent α -amylase may comprise a C-terminal part of an α -amylase derived from a strain of *B. licheniformis*, and a N-terminal part of an α -amylase derived from a strain of
20 *B. amyloliquefaciens* or from a strain of *B. stearothermophilus*. For instance, the parent α -amylase may comprise at least 430 amino acid residues of the C-terminal part of the *B. licheniformis* α -amylase. A such hybrid Termamyl-like α -amylase may be identical to the *Bacillus licheniformis* α -amylase shown
25 in SEQ ID NO: 4, except that the N-terminal 35 amino acid residues (of the mature protein) is replaced with the N-terminal 33 amino acid residues of the mature protein of the *Bacillus amyloliquefaciens* α -amylase (BAN) shown in SEQ ID NO: 5. A such hybrid may also consist of an amino acid segment corresponding
30 to the 68 N-terminal amino acid residues of the *B. stearothermophilus* α -amylase having the amino acid sequence shown in SEQ ID NO: 3 and an amino acid segment corresponding to the 415 C-terminal amino acid residues of the *B. licheniformis* α -amylase

having the amino acid sequence shown in SEQ ID NO: 4.

The non-Termamyl-like α -amylase may, e.g., be a fungal α -amylase, a mammalian or a plant α -amylase or a bacterial α -amylase (different from a Termamyl-like α -amylase). Specific
5 examples of such α -amylases include the *Aspergillus oryzae* TAKA α -amylase, the *A. niger* acid α -amylase, the *Bacillus subtilis* α -amylase, the porcine pancreatic α -amylase and a barley α -amylase. All of these α -amylases have elucidated structures which are markedly different from the structure of a typical
10 Termamyl-like α -amylase as referred to herein.

The fungal α -amylases mentioned above, i.e. derived from *A. niger* and *A. oryzae*, are highly homologous on the amino acid level and generally considered to belong to the same family of α -amylases. The fungal α -amylase derived from *Aspergillus*
15 *oryzae* is commercially available under the tradename Fungamyl™.

Furthermore, when a particular variant of a Termamyl-like α -amylase (variant of the invention) is referred to - in a conventional manner - by reference to modification (e.g., deletion or substitution) of specific amino acid residues in the
20 amino acid sequence of a specific Termamyl-like α -amylase, it is to be understood that variants of another Termamyl-like α -amylase modified in the equivalent position(s) (as determined from the best possible amino acid sequence alignment between the respective amino acid sequences) are encompassed thereby.

25 A preferred embodiment of a variant of the invention is one derived from a *B. licheniformis* α -amylase (as parent Termamyl-like α -amylase), e.g., one of those referred to above, such as the *B. licheniformis* α -amylase having the amino acid sequence shown in SEQ ID NO: 4.

30

Altered properties of variants of the invention

The following discusses the relationship between alterations/mutations which may be present in variants of the invention, and desirable alterations in properties (relative to

those a parent, Termamyl-like α -amylase) which may result therefrom.

Increased stability at acidic pH and/or low calcium
5 concentration at high temperatures

sub
B3
The present invention relates to a variant of a parent Termamyl-like α -amylase, which variant α -amylase has been altered in comparison to the parent α -amylase in one or more solvent exposed amino acid residues on the surface of the α -
10 amylase to increase the overall hydrophobicity of the α -amylase and/or to increase the overall numbers of methyl groups in the sidechains of said solvent exposed amino acid residues on the surface.

In a preferred embodiment one or more solvent exposed amino
15 acid residues on a concav surface with inwards bend are altered to more hydrophobic amino acid residues.

In another preferred embodiment one or more solvent exposed amino acid residues on a convex surface are altered to increase the number of methyl groups in the sidechain.

20 The present invention relates to an α -amylase variant of a parent Termamyl-like α -amylase, comprising an alteration at one or more positions selected from the group of:

E376, S417, A420, S356, Y358;

wherein (a) the alteration(s) are independently

25 (i) an insertion of an amino acid downstream of the amino acid which occupies the position,

(ii) a deletion of the amino acid which occupies the position, or

(iii) a substitution of the amino acid which occupies the
30 position with a different amino acid,

(b) the variant has α -amylase activity and (c) each position corresponds to a position of the amino acid sequence of the parent Termamyl-like α -amylase having the amino acid sequence of SEQ ID NO: 4.

35 In an embodiment the alteration is one of the following

substitutions:

E376A,R,D,C,Q,G,H,I,K,L,M,N,F,P,S,T,W,Y,V.

In a preferred embodiment the substitution is: E376K.

In an embodiment the alteration is one of the following
5 substitutions: S417A,R,D,C,E,Q,G,H,I,K,L,M,N,F,P,T,W,Y,V;

In a preferred embodiment the substitution is S417T.

In an embodiment the alteration is one of the following
substitutions A420R,D,C,E,Q,G,H,I,K,L,M,N,F,P,S,T,W,Y,V;

In a preferred embodiment the substitution is: A420Q,R.

10 In an embodiment the alteration is one of the following
substitutions: S356A,R,D,C,E,Q,G,H,I,K,L,M,N,F,P,T,W,Y,V.

In an embodiment the alteration is one of the following
substitutions Y358A,R,D,C,E,Q,G,H,I,K,L,M,N,F,P,S,T,W,V.

In a preferred embodiment the substitution is Y358F.

15 In an embodiment of the invention a variant comprises one or
more of the following substitutions: E376K, S417T, A420Q,R,
S356A, Y358F.

The increase in stability at acidic pH and/or low calcium
concentration at high temperatures may be determined using the
20 method described below in Example 2 illustrating the invention.

The parent Termamyl-like α -amylase used as the backbone for
preparing variants of the invention may be any Termamyl-like α -
amylases as defined above.

Specifically contemplated are parent Termamyl-like α -
25 amylases selected from the group derived from *B. licheniformis*,
such as *B. licheniformis* strain ATCC 27811, *B. amyloli-*
quefaciens, *B. stearothermophilus*, *Bacillus* sp. NCIB 12289, NCIB
12512, NCIB 12513 or DSM 9375, and the parent Termamyl-like α -
amylases depicted in SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7 and 8.

30 In an embodiment of the invention the parent Termamyl-like
 α -amylase is a hybrid α -amylase being identical to the *Bacillus*
licheniformis α -amylase shown in SEQ ID NO: 4 (Termamyl), except
that the N-terminal 35 amino acid residues (of the mature
protein) is replaced with the N-terminal 33 amino acid residues
35 of the mature protein of the *Bacillus amyloliquefaciens* α -
amylase (BAN) shown in SEQ ID NO: 5. The parent Termamyl-like

15

hybrid α -amylase may be the above mentioned hybrid Termamyl-like α -amylase which further has the following mutations: H156Y+181T+190F+209V+264S (using the numbering in SEQ ID NO: 4). Said backbone is referred to below as "LE174".

- 5 The parent α -amylase may advantageously further have a mutation in one or more of the following positions: K176, I201 and H205 (using the numbering in SEQ ID NO: 4), especially one or more the following substitutions: K176R, I201F, and H205N (using the numbering in SEQ ID NO: 4), such as specifically the
10 following substitutions: K176R+I201F+H205N (using the numbering in SEQ ID NO: 4).

The inventors have found that the above mentioned variants have increased stability at pHs below 7.0 (i.e., acidic pH) and/or at calcium concentration below 1mM (40ppm) (i.e., low
15 calcium concentrations) at temperatures in the range from 95 to 160°C (i.e., high temperatures) relative to the parent Termamyl-like α -amylase.

Alterations (e.g., by substitution) of one or more solvent exposed amino acid residues which 1) increase the overall
20 hydrophobicity of the enzyme, or 2) increase the number of methyl groups in the sidechains of the solvent exposed amino acid residues improve the temperature stability. It is preferred to alter (e.g., by substitution) to more hydrophobic residues on a concav surface with inwards bend. On a convex surface
25 alterations (e.g., by substitution) to amino acid residues with an increased number of methyl groups in the sidechain are preferred.

Using the program CAST found on the internet at <http://sunrise.cbs.umn.edu/cast/> version 1.0 (release Feb.
30 1998), (reference: Jie Liang, Herbert Edelsbrunner, and Clare Woodward. 1998. Anatomy of protein Pockets and Cavities: Measurements of binding site geometry and implications for ligand design. Protein Science, 7, pp. 1884-1897), a concave area which access to the surface can be identified. Access to
35 the surface is in the program defined as a probe with a diameter of 1.4Å can pass in and out. Using default parameters in the

CAST program can cave cavities can be found using the Calcium depleted alpha-amylase structure from *B. licheniformis* as found in the Brookhaven database (1BPL):

Three types of interaction can be rationalised:

- 5 A. Interaction between the sidechain of the residue and the protein,
- B. Interaction between the sidechain of the residue and the surrounding water,
- C. Interaction between the water and the protein.

10 Using the parent Termamyl-like α -amylase shown in SEQ ID NO: 4 as the backbone the following positions are considered to be solvent exposed and may suitably be altered:

E376, S417, A420, S356, Y358.

Corresponding and other solvent exposed positions on the
15 surface of other Termamyl-like α -amylase may be identified using the dssp program by W. Kabsch and C. Sander, Biopolymers 22 (1983) pp. 2577-2637. The convex surfaces can be identified using the the AACAVI program part from the WHATIF package (G. Vriend, Whatif and drug design program. J. Mol. Graph. 8, pp.
20 52-56. (1990) version 19980317).

In an embodiment of the invention a variant comprises one or more of the following substitutions: E376K, S417T, A420Q,R, S356A, Y358F.

The inventors have found that the stability at acidic pH
25 and/or low calcium concentration at high temperatures may be increased even more by combining mutations in the above mentioned positions, i.e., E376, S417, A420, S356, Y358, (using the SEQ ID NO: 4 numbering) with mutations in one or more of positions K176, I201, and H205.

30 The following additional substitutions are preferred:

K176A,R,D,C,E,Q,G,H,I,L,M,N,F,P,S,T,W,Y,V;

I201A,R,D,C,E,Q,G,H,L,K,M,N,F,P,S,T,W,Y,V;

H205A,R,D,C,E,Q,G,I,L,K,M,N,F,P,S,T,W,Y,V;

As also shown in Example 2 illustrating the invention
35 combining the following mutations give increased stability:

K176+I201F+H205N+E376K+A420R or

K176+I201F+H205N+S417T+A420Q or

K176+I201F+H205N+S356A+Y358F using the hybrid α -amylase referred to as LE174 as the parent Termamyl-like α -amylase.

5 General mutations in variants of the invention

It may be preferred that a variant of the invention comprises one or more modifications in addition to those outlined above. Thus, it may be advantageous that one or more proline residues present in the part of the α -amylase variant
10 which is modified is/are replaced with a non-proline residue which may be any of the possible, naturally occurring non-proline residues, and which preferably is an alanine, glycine, serine, threonine, valine or leucine.

Analogously, it may be preferred that one or more cysteine
15 residues present among the amino acid residues with which the parent α -amylase is modified is/are replaced with a non-cysteine residue such as serine, alanine, threonine, glycine, valine or leucine.

Furthermore, a variant of the invention may - either as the
20 only modification or in combination with any of the above outlined modifications - be modified so that one or more Asp and/or Glu present in an amino acid fragment corresponding to the amino acid fragment 185-209 of SEQ ID NO: 4 is replaced by an Asn and/or Gln, respectively. Also of interest is the
25 replacement, in the Termamyl-like α -amylase, of one or more of the Lys residues present in an amino acid fragment corresponding to the amino acid fragment 185-209 of SEQ ID NO: 4 by an Arg.

It will be understood that the present invention encompasses variants incorporating two or more of the above outlined
30 modifications.

Furthermore, it may be advantageous to introduce point-mutations in any of the variants described herein.

Cloning a DNA sequence encoding an α -amylase of the invention

The DNA sequence encoding a parent α -amylase may be isolated from any cell or microorganism producing the α -amylase in question, using various methods well known in the art. First, a genomic DNA and/or cDNA library should be constructed using chromosomal DNA or messenger RNA from the organism that produces the α -amylase to be studied. Then, if the amino acid sequence of the α -amylase is known, homologous, labelled oligonucleotide probes may be synthesized and used to identify α -amylase-encoding clones from a genomic library prepared from the organism in question. Alternatively, a labelled oligonucleotide probe containing sequences homologous to a known α -amylase gene could be used as a probe to identify α -amylase-encoding clones, using hybridization and washing conditions of lower stringency.

Yet another method for identifying α -amylase-encoding clones would involve inserting fragments of genomic DNA into an expression vector, such as a plasmid, transforming α -amylase-negative bacteria with the resulting genomic DNA library, and then plating the transformed bacteria onto agar containing a substrate for α -amylase, thereby allowing clones expressing the α -amylase to be identified.

Alternatively, the DNA sequence encoding the enzyme may be prepared synthetically by established standard methods, e.g. the phosphoroamidite method described by S.L. Beaucage and M.H. Caruthers (1981) or the method described by Matthes et al. (1984). In the phosphoroamidite method, oligonucleotides are synthesized, e.g., in an automatic DNA synthesizer, purified, annealed, ligated and cloned in appropriate vectors.

Finally, the DNA sequence may be of mixed genomic and synthetic origin, mixed synthetic and cDNA origin or mixed genomic and cDNA origin, prepared by ligating fragments of synthetic, genomic or cDNA origin (as appropriate, the fragments corresponding to various parts of the entire DNA sequence), in accordance with standard techniques. The DNA sequence may also be prepared by polymerase chain reaction (PCR) using specific

primers, for instance as described in US 4,683,202 or R.K. Saiki et al. (1988).

Site-directed mutagenesis

5 Once an a-amylase-encoding DNA sequence has been isolated, and desirable sites for mutation identified, mutations may be introduced using synthetic oligonucleotides. These oligonucleotides contain nucleotide sequences flanking the desired mutation sites; mutant nucleotides are inserted during oligonucleotide
10 synthesis. In a specific method, a single-stranded gap of DNA, bridging the a-amylase-encoding sequence, is created in a vector carrying the a-amylase gene. Then the synthetic nucleotide, bearing the desired mutation, is annealed to a homologous portion of the single-stranded DNA. The remaining gap is then
15 filled in with DNA polymerase I (Klenow fragment) and the construct is ligated using T4 ligase. A specific example of this method is described in Morinaga et al. (1984). US 4,760,025 discloses the introduction of oligonucleotides encoding multiple mutations by performing minor alterations of the cassette. How-
20 ever, an even greater variety of mutations can be introduced at any one time by the Morinaga method, because a multitude of oligonucleotides, of various lengths, can be introduced.

Another method for introducing mutations into a-amylase-encoding DNA sequences is described in Nelson and Long (1989).
25 It involves the 3-step generation of a PCR fragment containing the desired mutation introduced by using a chemically synthesized DNA strand as one of the primers in the PCR reactions. From the PCR-generated fragment, a DNA fragment carrying the mutation may be isolated by cleavage with restriction
30 endonucleases and reinserted into an expression plasmid.

Random Mutagenesis

Random mutagenesis is suitably performed either as localised or region-specific random mutagenesis in at least three parts of the gene translating to the amino acid sequence shown in question, or within the whole gene.

The random mutagenesis of a DNA sequence encoding a parent α -amylase may be conveniently performed by use of any method known in the art.

In relation to the above, a further aspect of the present invention relates to a method for generating a variant of a parent α -amylase, e.g., wherein the variant exhibits altered or increased thermal stability relative to the parent, the method comprising:

- (a) subjecting a DNA sequence encoding the parent α -amylase to random mutagenesis,
- (b) expressing the mutated DNA sequence obtained in step (a) in a host cell, and
- (c) screening for host cells expressing an α -amylase variant which has an altered property (i.e. thermal stability) relative to the parent α -amylase.

Step (a) of the above method of the invention is preferably performed using doped primers.

For instance, the random mutagenesis may be performed by use of a suitable physical or chemical mutagenizing agent, by use of a suitable oligonucleotide, or by subjecting the DNA sequence to PCR generated mutagenesis. Furthermore, the random mutagenesis may be performed by use of any combination of these mutagenizing agents. The mutagenizing agent may, e.g., be one which induces transitions, transversions, inversions, scrambling, deletions, and/or insertions.

Examples of a physical or chemical mutagenizing agent suitable for the present purpose include ultraviolet (UV) irradiation, hydroxylamine, N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), O-methyl hydroxylamine, nitrous acid, ethyl methane sulphonate (EMS), sodium bisulphite, formic acid, and nucleotide analogues. When such agents are used, the mutagenesis is typically performed by incubating the DNA sequence encoding the parent enzyme to be mutagenized in the presence of the mutagenizing agent of choice under suitable conditions for the mutagenesis to take place, and selecting for mutated DNA having the desired properties.

When the mutagenesis is performed by the use of an oligonucleotide, the oligonucleotide may be doped or spiked with the three non-parent nucleotides during the synthesis of the oligonucleotide at the positions which are to be changed. The doping or spiking may be done so that codons for unwanted amino acids are avoided. The doped or spiked oligonucleotide can be incorporated into the DNA encoding the alpha-amylase enzyme by any published technique, using e.g. PCR, LCR or any DNA polymerase and ligase as deemed appropriate.

Preferably, the doping is carried out using "constant random doping", in which the percentage of wild-type and mutation in each position is predefined. Furthermore, the doping may be directed toward a preference for the introduction of certain nucleotides, and thereby a preference for the introduction of one or more specific amino acid residues. The doping may be made, e.g., so as to allow for the introduction of 90% wild type and 10% mutations in each position. An additional consideration in the choice of a doping scheme is based on genetic as well as protein-structural constraints. The doping scheme may be made by using the DOPE program which, *inter alia*, ensures that introduction of stop codons is avoided.

When PCR-generated mutagenesis is used, either a chemically treated or non-treated gene encoding a parent α -amylase is subjected to PCR under conditions that increase the mis-incorporation of nucleotides (Deshler 1992; Leung et al., Technique, Vol.1, 1989, pp. 11-15).

A mutator strain of *E. coli* (Fowler et al., Molec. Gen. Genet., 133, 1974, pp. 179-191), *S. cerevisiae* or any other microbial organism may be used for the random mutagenesis of the DNA encoding the α -amylase by, e.g., transforming a plasmid
5 containing the parent glycosylase into the mutator strain, growing the mutator strain with the plasmid and isolating the mutated plasmid from the mutator strain. The mutated plasmid may be subsequently transformed into the expression organism.

The DNA sequence to be mutagenized may be conveniently
10 present in a genomic or cDNA library prepared from an organism expressing the parent alpha-amylase. Alternatively, the DNA sequence may be present on a suitable vector such as a plasmid or a bacteriophage, which as such may be incubated with or other-wise exposed to the mutagenising agent. The DNA to be
15 mutagenized may also be present in a host cell either by being integrated in the genome of said cell or by being present on a vector harboured in the cell. Finally, the DNA to be mutagenized may be in isolated form. It will be understood that the DNA sequence to be subjected to random mutagenesis is preferably a
20 cDNA or a genomic DNA sequence.

In some cases it may be convenient to amplify the mutated DNA sequence prior to performing the expression step b) or the screening step c). Such amplification may be performed in accordance with methods known in the art, the presently
25 preferred method being PCR-generated amplification using oligonucleotide primers prepared on the basis of the DNA or amino acid sequence of the parent enzyme.

Subsequent to the incubation with or exposure to the mutagenising agent, the mutated DNA is expressed by culturing a suitable host cell carrying the DNA sequence under conditions allowing expression to take place. The host cell used for this purpose may be one which has been transformed with the mutated DNA sequence, optionally present on a vector, or one which was carried the DNA sequence encoding the parent enzyme during the mutagenesis treatment. Examples of suitable host cells are the following: gram positive bacteria such as *Bacillus subtilis*,
10 *Bacillus licheniformis*, *Bacillus lentus*, *Bacillus brevis*, *Bacillus stearothermophilus*, *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus coagulans*, *Bacillus circulans*, *Bacillus lautus*, *Bacillus megaterium*, *Bacillus thuringiensis*, *Streptomyces lividans* or *Streptomyces murinus*; and gram-negative
15 bacteria such as *E. coli*.

The mutated DNA sequence may further comprise a DNA sequence encoding functions permitting expression of the mutated DNA sequence.

20 Localized random mutagenesis

The random mutagenesis may be advantageously localized to a part of the parent α -amylase in question. This may, e.g., be advantageous when certain regions of the enzyme have been identified to be of particular importance for a given property
25 of the enzyme, and when modified are expected to result in a variant having improved properties. Such regions may normally be identified when the tertiary structure of the parent enzyme has been elucidated and related to the function of the enzyme.

The localized, or region-specific, random mutagenesis is
30 conveniently performed by use of PCR generated mutagenesis techniques as described above or any other suitable technique known in the art. Alternatively, the DNA sequence encoding the part of the DNA sequence to be modified may be isolated, e.g., by insertion into a suitable vector, and said part may be
35 subsequently subjected to mutagenesis by use of any of the mutagenesis methods discussed above.

Alternative methods of providing α -amylase variants

Alternative methods for providing variants of the invention include gene shuffling method known in the art including the methods, e.g., described in WO 95/22625 (from Affymax Technologies N.V.) and WO 96/00343 (from Novo Nordisk A/S).

Expression of α -amylase variants of the invention

According to the invention, a DNA sequence encoding the variant produced by methods described above, or by any alternative methods known in the art, can be expressed, in enzyme form, using an expression vector which typically includes control sequences encoding a promoter, operator, ribosome binding site, translation initiation signal, and, optionally, a repressor gene or various activator genes.

The recombinant expression vector carrying the DNA sequence encoding an α -amylase variant of the invention may be any vector which may conveniently be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced. Thus, the vector may be an autonomously replicating vector, i.e., a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid, a bacteriophage or an extrachromosomal element, minichromosome or an artificial chromosome. Alternatively, the vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated.

In the vector, the DNA sequence should be operably connected to a suitable promoter sequence. The promoter may be any DNA sequence which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell. Examples of suitable promoters for directing the transcription of the DNA sequence encoding an α -amylase variant of the invention, especially in a bacterial host, are the promoter of the lac operon of *E.coli*, the *Streptomyces coelicolor* agarase gene *dagA*

promoters, the promoters of the *Bacillus licheniformis* α -amylase gene (*amyL*), the promoters of the *Bacillus stearothermophilus* maltogenic amylase gene (*amyM*), the promoters of the *Bacillus amyloliquefaciens* α -amylase (*amyQ*), the promoters of the *Bacillus subtilis* *xylA* and *xylB* genes etc. For transcription in a fungal host, examples of useful promoters are those derived from the gene encoding *A. oryzae* TAKA amylase, *Rhizomucor miehei* aspartic proteinase, *A. niger* neutral α -amylase, *A. niger* acid stable α -amylase, *A. niger* glucoamylase, *Rhizomucor miehei* lipase, *A. oryzae* alkaline protease, *A. oryzae* triose phosphate isomerase or *A. nidulans* acetamidase.

The expression vector of the invention may also comprise a suitable transcription terminator and, in eukaryotes, polyadenylation sequences operably connected to the DNA sequence encoding the α -amylase variant of the invention. Termination and polyadenylation sequences may suitably be derived from the same sources as the promoter.

The vector may further comprise a DNA sequence enabling the vector to replicate in the host cell in question. Examples of such sequences are the origins of replication of plasmids pUC19, pACYC177, pUB110, pE194, pAMB1 and pIJ702.

The vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect in the host cell, such as the *dal* genes from *B. subtilis* or *B. licheniformis*, or one which confers antibiotic resistance such as ampicillin, kanamycin, chloramphenicol or tetracyclin resistance. Furthermore, the vector may comprise *Aspergillus* selection markers such as *amdS*, *argB*, *niaD* and *sC*, a marker giving rise to hygromycin resistance, or the selection may be accomplished by co-transformation, e.g. as described in WO 91/17243.

While intracellular expression may be advantageous in some respects, e.g. when using certain bacteria as host cells, it is generally preferred that the expression is extracellular. In general, the *Bacillus* α -amylases mentioned herein comprise a preregion permitting secretion of the expressed protease into the culture medium. If desirable, this preregion may be replaced

by a different preregion or signal sequence, conveniently accomplished by substitution of the DNA sequences encoding the respective preregions.

The procedures used to ligate the DNA construct of the invention encoding an α -amylase variant, the promoter, terminator and other elements, respectively, and to insert them into suitable vectors containing the information necessary for replication, are well known to persons skilled in the art (cf., for instance, Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor, 1989).

The cell of the invention, either comprising a DNA construct or an expression vector of the invention as defined above, is advantageously used as a host cell in the recombinant production of an α -amylase variant of the invention. The cell may be transformed with the DNA construct of the invention encoding the variant, conveniently by integrating the DNA construct (in one or more copies) in the host chromosome. This integration is generally considered to be an advantage as the DNA sequence is more likely to be stably maintained in the cell. Integration of the DNA constructs into the host chromosome may be performed according to conventional methods, e.g. by homologous or heterologous recombination. Alternatively, the cell may be transformed with an expression vector as described above in connection with the different types of host cells.

The cell of the invention may be a cell of a higher organism such as a mammal or an insect, but is preferably a microbial cell, e.g., a bacterial or a fungal (including yeast) cell.

Examples of suitable bacteria are grampositive bacteria such as *Bacillus subtilis*, *Bacillus licheniformis*, *Bacillus lentus*, *Bacillus brevis*, *Bacillus stearothermophilus*, *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus coagulans*, *Bacillus circulans*, *Bacillus lautus*, *Bacillus megaterium*, *Bacillus thuringiensis*, or *Streptomyces lividans* or *Streptomyces murinus*, or gramnegative bacteria such as *E.coli*. The transformation of the bacteria may, for instance, be effected by protoplast transformation or by using competent cells in a manner known per se.

The yeast organism may favourably be selected from a species of *Saccharomyces* or *Schizosaccharomyces*, e.g. *Saccharomyces cerevisiae*. The filamentous fungus may advantageously belong to a species of *Aspergillus*, e.g. *Aspergillus oryzae* or *Aspergillus niger*. Fungal cells may be transformed by a process involving protoplast formation and transformation of the protoplasts followed by regeneration of the cell wall in a manner known *per se*. A suitable procedure for transformation of *Aspergillus* host cells is described in EP 238 023.

In a yet further aspect, the present invention relates to a method of producing an α -amylase variant of the invention, which method comprises cultivating a host cell as described above under conditions conducive to the production of the variant and recovering the variant from the cells and/or culture medium.

The medium used to cultivate the cells may be any conventional medium suitable for growing the host cell in question and obtaining expression of the α -amylase variant of the invention. Suitable media are available from commercial suppliers or may be prepared according to published recipes (e.g., as described in catalogues of the American Type Culture Collection).

The α -amylase variant secreted from the host cells may conveniently be recovered from the culture medium by well-known procedures, including separating the cells from the medium by centrifugation or filtration, and precipitating proteinaceous components of the medium by means of a salt such as ammonium sulphate, followed by the use of chromatographic procedures such as ion exchange chromatography, affinity chromatography, or the like.

Industrial Applications

The α -amylase variants of this invention possesses valuable properties allowing for a variety of industrial applications. An enzyme variant of the invention are applicable as a component in washing, dishwashing and hard-surface cleaning detergent compositions. Numerous variants are particularly useful in the production of sweeteners and ethanol from starch, and/or for

textile desizing. Conditions for conventional starch- conversion processes, including starch liquefaction and/or saccharification processes, are described in, e.g., US 3,912,590 and in EP patent publications Nos. 252,730 and 63,909.

5

Production of sweeteners from starch:

A "traditional" process for conversion of starch to fructose syrups normally consists of three consecutive enzymatic processes, viz. a liquefaction process followed by a sacchari-
10 fication process and an isomerization process. During the liquefaction process, starch is degraded to dextrans by an α -amylase (e.g. Termamyl™) at pH values between 5.5 and 6.2 and at temperatures of 95-160°C for a period of approx. 2 hours. In order to ensure an optimal enzyme stability under these condi-
15 tions, 1 mM of calcium is added (40 ppm free calcium ions).

After the liquefaction process the dextrans are converted into dextrose by addition of a glucoamylase (e.g. AMG™) and a debranching enzyme, such as an isoamylase or a pullulanase (e.g. Promozyme™). Before this step the pH is reduced to a value below
20 4.5, maintaining the high temperature (above 95°C), and the liquefying α -amylase activity is denatured. The temperature is lowered to 60°C, and glucoamylase and debranching enzyme are added. The saccharification process proceeds for 24-72 hours.

After the saccharification process the pH is increased to a
25 value in the range of 6-8, preferably pH 7.5, and the calcium is removed by ion exchange. The dextrose syrup is then converted into high fructose syrup using, e.g., an immobilized gluco-seisomerase (such as Sweetzyme™).

At least 1 enzymatic improvements of this process could be
30 envisaged. Reduction of the calcium dependency of the liquefying α -amylase. Addition of free calcium is required to ensure adequately high stability of the α -amylase, but free calcium strongly inhibits the activity of the glucoseisomerase and needs to be removed, by means of an expensive unit
35 operation, to an extent which reduces the level of free calcium to below 3-5 ppm. Cost savings could be obtained if such an

operation could be avoided and the liquefaction process could be performed without addition of free calcium ions.

To achieve that, a less calcium-dependent Termamyl-like α -amylase which is stable and highly active at low concentrations of free calcium (< 40 ppm) is required. Such a Termamyl-like α -amylase should have a pH optimum at a pH in the range of 4.5-6.5, preferably in the range of 4.5-5.5.

Detergent compositions

As mentioned above, variants of the invention may suitably be incorporated in detergent compositions. Reference is made, for example, to WO 96/23874 and WO 97/07202 for further details concerning relevant ingredients of detergent compositions (such as laundry or dishwashing detergents), appropriate methods of formulating the variants in such detergent compositions, and for examples of relevant types of detergent compositions.

Detergent compositions comprising a variant of the invention may additionally comprise one or more other enzymes, such as a lipase, cutinase, protease, cellulase, peroxidase or laccase, and/or another α -amylase.

α -amylase variants of the invention may be incorporated in detergents at conventionally employed concentrations. It is at present contemplated that a variant of the invention may be incorporated in an amount corresponding to 0.00001-1 mg (calculated as pure, active enzyme protein) of α -amylase per liter of wash/dishwash liquor using conventional dosing levels of detergent.

MATERIALS AND METHODS

Enzymes:

LE174 hybrid alpha-amylase variant: LE174 is a hybrid Termamyl-like alpha-amylase being identical to the Termamyl sequence, i.e., the *Bacillus licheniformis* α -amylase shown in SEQ ID NO: 4, except that the N-terminal 35 amino acid residues (of the mature protein) has been replaced by the N-terminal 33 residues of BAN (mature protein), i.e., the *Bacillus amyloliquefaciens*

alpha-amylase shown in SEQ ID NO: 5, which further have following mutations: H156Y+A181T+N190F+A209V+Q264S (using the numbering in SEQ ID NO: 4).

5 Construction of pSNK101

This *E. coli*/Bacillus shuttle vector can be used to introduce mutations without expression of α -amylase in *E. coli* and then be modified in such way that the α -amylase is active in Bacillus. The vector was constructed as follows: The α -amylase gene in the pX vector (pDN1528 with the following alterations within amyL: BAN(1-33), H156Y, A181T, N190F, A209V, Q264S, the plasmid pDN1528 is further described in Example 1) was inactivated by interruption in the PstI site in the 5' coding region of the alpha-amylase gene by a 1.2 kb fragment containing an *E. coli* origin fragment. This fragment was amplified from the pUC19 (GenBank Accession #:X02514) using the forward primer 1: 5'-gacctgcagtcaggcaacta-3' (SEQ ID NO: 28) and the reverse primer 1: 5'-tagagtcgacctgcaggcat-3' (SEQ ID NO: 29). The PCR amplicon and the pX plasmid containing the α -amylase gene were digested with PstI at 37°C for 2 hours. The pX vector fragment and the *E. coli* origin amplicon were ligated at room temperature for 1 hour and transformed in *E. coli* by electrotransformation. The resulting vector is designated pSnK101.

This *E. coli*/Bacillus shuttle vector can be used to introduce mutations without expression of α -amylase in *E. coli* and then be modified in such way that the α -amylase is active in Bacillus. The vector was constructed as follows: The α -amylase gene in the pX vector (pDN1528 with the following alterations within amyL: BAN(1-33), H156Y+A181T+N190F+A209V+Q264S, the plasmid pDN1528 is further described in Example 1) was inactivated by interruption in the PstI site in the 5' coding region of the alpha-amylase gene by a 1.2 kb fragment containing an *E. coli* origin fragment. This fragment was amplified from the pUC19 (GenBank Accession

#:X02514) using the forward primer 2: 5'-gacctgcagtcaggcaacta-3' (SEQ ID NO: 30) and the reverse primer 2: 5'-tagagtcgacctgcaggcat-3' (SEQ ID NO: 31). The PCR amplicon and the pX plasmid containing the α -amylase gene were digested with PstI at 37°C for 2 hours. The pX vector fragment and the *E. coli* origin amplicon were ligated at room temperature. for 1 hour and transformed in *E. coli* by electrotransformation. The resulting vector is designated pSnK101.

10 Low pH filter assay

Bacillus libraries are plated on a sandwich of cellulose acetate (OE 67, Schleicher & Schuell, Dassel, Germany) - and nitrocellulose filters (Protran-Ba 85, Schleicher & Schuell, Dassel, Germany) on TY agar plates with 10 μ g/ml chloramphenicol at 37°C for at least 21 hrs. The cellulose acetate layer is located on the TY agar plate.

Each filter sandwich is specifically marked with a needle after plating, but before incubation in order to be able to localize positive variants on the filter and the nitrocellulose filter with bound variants is transferred to a container with citrate buffer, pH 4.5 and incubated at 90°C for 15 min. The cellulose acetate filters with colonies are stored on the TY-plates at room temperature until use. After incubation, residual activity is detected on assay plates containing 1% agarose, 0.2% starch in citrate buffer, pH 6.0. The assay plates with nitrocellulose filters are marked the same way as the filter sandwich and incubated for 2 hours. at 50°C. After removal of the filters the assay plates are stained with 10% Lugol solution. Starch degrading variants are detected as white spots on dark blue background and then identified on the storage plates. Positive variants are rescreened twice under the same conditions as the first screen.

Secondary screening

Positive transformants after rescreening are picked from the storage plate and tested in a secondary plate assay.

Positive transformants are grown for 22 hours at 37°C in 5 ml LB + chloramphenicol. The *Bacillus* culture of each positive transformant and a control LE174 variant were incubated in citrate buffer, pH 4.5 at 90°C and samples were taken at 5 0,10,20,30,40,60 and 80 minutes. A 3 microliter sample was spotted on a assay plate. The assay plate was stained with 10% Lugol solution. Improved variants were seen as variants with higher residual activity detected as halos on the assay plate than the backbone. The improved variants are determined by 10 nucleotide sequencing.

Fermentation and purification of α -amylase variants

A *B. subtilis* strain harbouring the relevant expression plasmid is streaked on a LB-agar plate with 15 μ g/ml 15 chloramphenicol from -80°C stock, and grown overnight at 37°C. The colonies are transferred to 100 ml BPX media supplemented with 15 μ g/ml chloramphenicol in a 500 ml shaking flask.

Composition of BPX medium:

	Potato starch	100 g/l
20	Barley flour	50 g/l
	BAN 5000 SKB	0.1 g/l
	Sodium caseinate	10 g/l
	Soy Bean Meal	20 g/l
	Na ₂ HPO ₄ , 12 H ₂ O	9 g/l
25	Pluronic™	0.1 g/l

The culture is shaken at 37°C at 270 rpm for 5 days.

Cells and cell debris are removed from the fermentation broth by centrifugation at 4500 rpm in 20-25 minutes. Afterwards the supernatant is filtered to obtain a completely clear 30 solution. The filtrate is concentrated and washed on a UF-filter (10000 cut off membrane) and the buffer is changed to 20mM Acetate pH 5.5. The UF-filtrate is applied on a S-sepharose F.F. and elution is carried out by step elution with 0.2M NaCl in the same buffer. The eluate is dialysed against 10mM Tris, pH 35 9.0 and applied on a Q-sepharose F.F. and eluted with a linear gradient from 0-0.3M NaCl over 6 column volumes. The fractions

which contain the activity (measured by the Phadebas assay) are pooled, pH was adjusted to pH 7.5 and remaining color was removed by a treatment with 0.5% W/vol. active coal in 5 minutes.

5

Stability determination

All the stability trials are made using the same set up. The method is:

The enzyme is incubated under the relevant conditions (1-10 4). Samples are taken at 0, 5, 10, 15 and 30 minutes and diluted 25 times (same dilution for all taken samples) in assay buffer (0.1M 50mM Britton buffer pH 7.3) and the activity is measured using the Phadebas assay (Pharmacia) under standard conditions pH 7.3, 37°C.

15 The activity measured before incubation (0 minutes) is used as reference (100%). The decline in percent is calculated as a function of the incubation time. The table shows the residual activity after 30 minutes of incubation.

20 Activity determination - (KNU)

One Kilo alph-amylase Unit (1 KNU) is the amount of enzyme which breaks down 5.26 g starch (Merck, Amylum Solubile, Erg. B 6, Batch 9947275) per hour in Novo Nordisk's standard method for determination of alpha-amylase based upon the following 25 condition:

Substrate	soluble starch
Calcium content in solvent	0.0043 M
Reaction time	7-20 minutes
Temperature	37°C
30 pH	5.6

Detailed description of Novo Nordisk's analytical method (AF 9) is available on request.

Specific activity determination

35 Assay for α -Amylase Activity

α -amylase activity is determined by a method employing Phadebas® tablets as substrate. Phadebas tablets

(Phadebas® Amylase Test, supplied by Pharmacia Diagnostic) contain a cross-linked insoluble blue-coloured starch polymer which has been mixed with bovine serum albumin and a buffer substance and tabletted.

5 For every single measurement one tablet is suspended in a tube containing 5 ml 50 mM Britton-Robinson buffer (50 mM acetic acid, 50 mM phosphoric acid, 50 mM boric acid, 0.1 mM CaCl_2 , pH adjusted to the value of interest with NaOH). The test is performed in a water bath at the temperature of interest. The
10 α -amylase to be tested is diluted in x ml of 50 mM Britton-Robinson buffer. 1 ml of this α -amylase solution is added to the 5 ml 50 mM Britton-Robinson buffer. The starch is hydrolysed by the α -amylase giving soluble blue fragments. The absorbance of the resulting blue solution, measured spectrophotometrically at
15 620 nm, is a function of the α -amylase activity.

It is important that the measured 620 nm absorbance after 10 or 15 minutes of incubation (testing time) is in the range of 0.2 to 2.0 absorbance units at 620 nm. In this absorbance range there is linearity between activity and
20 absorbance (Lambert-Beer law). The dilution of the enzyme must therefore be adjusted to fit this criterion. Under a specified set of conditions (temp., pH, reaction time, buffer conditions) 1 mg of a given α -amylase will hydrolyse a certain amount of substrate and a blue colour will be produced. The colour
25 intensity is measured at 620 nm. The measured absorbance is directly proportional to the specific activity (activity/mg of pure α -amylase protein) of the α -amylase in question under the given set of conditions.

30 EXAMPLES

Example 1.

Construction, by random mutagenesis, of Termamyl-like LE174 α -amylase variants having an improved stability at low pH and a reduced dependency on calcium ions for stability compared to the parent enzyme.

5

Random mutagenesis

To improve the stability at low pH and low calcium concentration of the parent LE174 α -amylase variant random mutagenesis in preselected regions was performed.

10 The regions were:

Region:	Residue:
SERI	A425-Y438
SERII	W411-L424
SERIII	G397-G410
15 SERV	T369-H382
SERVII	G310-F323
SERIX	L346-P359

For each six region, random oligonucleotides are synthesized using the same mutation rate (97 % backbone and 1% of each of the three remaining nucleotides giving 3% mutations) in each nucleotide position in the above regions, e.g., 1. position in codon for A425: 97%C, 1%A, 1%T, 1%G. The six random oligonucleotides and if used complementary SOE helping primers are shown in tables 1-6: with the four distribution of 25 nucleotides below.

Table 1.

RSERI: 5'-GC GTT TTG CCG GCC GAC ATA 312 234 322 243 333 133
444 233 423 242 212 211 243 343 CAA ACC TGA ATT-3' (SEQ ID NO:
30 15)

Table 2.

RSERII: 5'-GC GTT TTG CCG GCC GAC ATA CAT TCG CTT TGC CCC ACC
GGG TCC GTC TGT TAT TAA TGC CGC 311 133 241 122 243 113 341 432
35 423 433 223 332 242 331 GCC GAC AAT GTC ATG GTG-3' (SEQ ID NO:
16)

Table 3.

RSERIII: 5'-GTC GCC TTC CCT TGT CCA 433 413 112 423 124 424 423
411 121 123 124 324 243 233 GTA CGC ATA CTG TTT TCT-3' (SEQ ID

s NO: 17)

Helping primer FSERIII: 5'-TGG ACA AGG GAA GGC GAC AG-3' (SEQ
ID NO: 18)

Table 4.

10 RSEV: 5-TAA GAT CGG TTC AAT TTT 424 222 311 443 144 112 223
434 324 441 423 233 222 342 CCC GTA CAT ATC CCC GTA GAA-3 (SEQ
ID NO: 19)

Helping primer FSEV: 5-AAA ATT GAA CCG ATC TTA-3 (SEQ ID NO:
20)

Table 5.

FSERVII: 5'-TT CCA TGC TGC ATC GAC ACA GGG AGG CGG CTA TGA TAT
GAG GAA ATT GCT GAA 344 213 442 342 223 311 431 233 422 411 123
442 213 122 TGT CGA TAA CCA-3' (SEQ ID NO: 21)

Helping primer RSEVII: 5'- TGT CGA TGC AGC ATG GAA - 3' (SEQ
ID NO: 22)

Table 6.

25 FSERIX: 5'-GT CCA AAC ATG GTT TAA GCC 432 243 221 343 222 212
232 313 114 441 123 244 121 333 TCA GGT TTT CTA CGG GGA-3' (SEQ
ID NO: 23)

Helping primer RSEIX: 5'-GGC TTA AAC CAT GTT TGG AC-3' (SEQ ID
NO: 24)

30

Distribution of nucleotides in each mutated nucleotide position

1:97%A, 1%T, 1%C, 1%G

2:97%T, 1%A, 1%C, 1%G

3:97%C, 1%A, 1%T, 1%G

35 4:97%G, 1%A, 1%T, 1%C

Construction of plasmid libraries

Two approximately 1.4 kb fragments were PCR amplified using the primer 1B: 5'-CGA TTG CTG ACG CTG TTA TTT GCG-3' and the random oligonucleotide apparent from table 1, respectively the random oligonucleotide apparent from table 2. The vector pSnK101 and the PCR fragments were digested with EcoRV and EagI for 2 hours. The approximately 3.6 kb vector fragment and the approximately 1.3 kb PCR fragments was purified and ligated overnight and transformed in to *E.coli* and then further transformed into a *Bacillus* host strain as described below. The random oligonucleotides apparent from Tables 3-6 (which by a common term is designated aSER and bSER in Fig. 2) for each region and specific *B. licheniformis* primers 1B (SEQ ID NO: 26) and #63: 5'-CTA TCT TTG AAC ATA AAT TGA AAC C-3' (SEQ ID NO: 27) covering the EcoRV and the EagI sites in the LE174 sequence are used to generate PCR-library-fragments by the overlap extension method (Horton et al., Gene, 77 (1989), pp. 61-68) Figure 2 shows the PCR strategy. The PCR fragments are cloned in the *E. coli*/*Bacillus* shuttle vector pSNK101 (see Materials and Methods) enabling mutagenesis in *E. coli* and immediate expression in *Bacillus subtilis* preventing lethal accumulation of amylases in *E. coli*. After establishing the cloned PCR fragments in *E. coli*, a modified pUC19 fragment is digested out of the plasmid and the promoter and the mutated Termamyl gene is physically connected and expression can take place in the *Bacillus* host .

Screening

The six libraries were screened in the low pH filter assays described in the "Material and Methods" section above.

All variants listed in the table in Example 2 below was prepared as described in Example 1.

EXAMPLE 2

Measurement of stability

Normally, industrial liquefaction processes is run at pH 6.0-6.2 with addition of about 40 ppm free calcium in order to

improve the stability at 95°C-105°C. Variants of the invention have been made in order to improve the stability at

1. lower pH than pH 6.2 and/or
2. at free calcium levels lower than 40ppm free calcium.

- 5 An assay which measures the stability at acidic pH, pH 5.0, in the presence of 5ppm free calcium was used to measure the increase in stability.

- 10 10 µg of the variant was incubated under the following conditions: A 0.1 M acetate solution, pH adjusted to pH 5.0, containing 5ppm calcium and 5% w/w common corn starch (free of calcium). Incubation was made in a water bath at 95°C for 30 minutes.

Results:

- 15 Increased stability at pH 5.0, 5 ppm calcium incubated at 95°C

MINUTES OF INCUBATION	LE174 WITH K176R+ I201F+ H205N	LE174 WITH K176R+ I201F+ H205N+ E376K+ A420R	LE174 WITH K176R+ I201F+ H205N+ S417T+ A420Q	LE174 WITH K176R+ I201F+ H205N+ S356A+ Y358F
0	100	100	100	100
5	65	61	66	66
10	58	53	60	59
15	51	48	55	56
30	36	39	45	49

Specific activity determination.

- The specific activity was determined using the Phadebas assay (Pharmacia) (described above) as activity/mg enzyme. The
20 activity was determined using the α-amylase assay described in the Materials and Methods section herein.

LE174 with the following substitutions:

39

K176R+I201F+H205N

Specific activity determined: 13400NU/mg

LE174 with the following substitutions:

5 K176R+I201F+H205N+E376K+A420R:

Specific activity determined: 14770NU/mg

LE174 with the following substitutions:

K176R+I201F+H205N+S417T+A420Q:

10 Specific activity determined: 16670NU/mg

LE174 with the following substitutions:

K176R+I201F+H205N+S356A+Y358F:

Specific activity determined: 15300NU/mg

SECRET

REFERENCES CITED

- Klein, C., et al., *Biochemistry* 1992, 31, 8740-8746,
Mizuno, H., et al., *J. Mol. Biol.* (1993) 234, 1282-1283,
Chang, C., et al., *J. Mol. Biol.* (1993) 229, 235-238,
5 Larson, S.B., *J. Mol. Biol.* (1994) 235, 1560-1584,
Lawson, C.L., *J. Mol. Biol.* (1994) 236, 590-600,
Qian, M., et al., *J. Mol. Biol.* (1993) 231, 785-799,
Brady, R.L., et al., *Acta Crystallogr. sect. B*, 47, 527-535,
Swift, H.J., et al., *Acta Crystallogr. sect. B*, 47, 535-544
10 A. Kadziola, Ph.D. Thesis: "An alpha-amylase from Barley and its
Complex with a Substrate Analogue Inhibitor Studied by X-ray
Crystallography", Department of Chemistry University of
Copenhagen 1993
MacGregor, E.A., *Food Hydrocolloids*, 1987, Vol.1, No. 5-6, p.
15 B. Diderichsen and L. Christiansen, Cloning of a maltogenic α -
amylase from *Bacillus stearothermophilus*, *FEMS Microbiol. let-*
ters: 56: pp. 53-60 (1988)
Hudson et al., *Practical Immunology*, Third edition (1989),
Blackwell Scientific Publications,
20 Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd
Ed., Cold Spring Harbor, 1989
S.L. Beaucage and M.H. Caruthers, Tetrahedron Letters 22, 1981,
pp. 1859-1869
Matthes et al., The EMBO J. 3, 1984, pp. 801-805.
25 R.K. Saiki et al., Science 239, 1988, pp. 487-491.
Morinaga et al., (1984, *Biotechnology* 2:646-639)
Nelson and Long, Analytical Biochemistry 180, 1989, pp. 147-151
Hunkapiller et al., 1984, *Nature* 310:105-111
R. Higuchi, B. Krummel, and R.K. Saiki (1988). A general method
30 of *in vitro* preparation and specific mutagenesis of DNA frag-
ments: study of protein and DNA interactions. *Nucl. Acids Res.*
16:7351-7367.
Dubnau et al., 1971, J. Mol. Biol. 56, pp. 209-221.
Gryczan et al., 1978, J. Bacteriol. 134, pp. 318-329.
35 S.D. Erlich, 1977, Proc. Natl. Acad. Sci. 74, pp. 1680-1682.
Boel et al., 1990, Biochemistry 29, pp. 6244-6249.